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Long non-coding RNAs (lncRNAs) refer to a class of RNA molecules with poor protein coding potential and are 
usually larger than 200 nucleotides. SPRY4-IT1, a member of lncRNA, is derived from an intronic region within 
the SPRY4 gene. And accumulating evidence demonstrates that aberrant expression of SPRY4-IT1 is involved in 
the development of various diseases such as melanoma, esophageal squamous cell carcinoma (ESCC), renal 
cancer, gastric cancer, breast cancer, bladder cancer, Non-small-cell lung cancer (NSCLC), and preeclampsia. 
SPRY4-IT1 is significantly related to not only progression and prognosis of diseases but also cell proliferation, 
migration, invasion. SPRY4-IT1 contributes to various diseases via different molecular mechanism such as 
regulating the expression of proteins related to cell growth and migration, involving in epithelial–mesenchymal 
transition (EMT), affecting lipid metabolism, and regulating downstream gene expression. Moreover, 
SPRY4-IT1 can also be regulated by some epigenetic factors including Zeste homolog 2 (EZH2). Therefore, 
SPRY4-IT1 may be a novel prognostic biomarker and a potential therapeutic candidate for different diseases 
including various solid cancers and preeclampsia. 
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Introduction 
While only 1.5% of the human genome has been reported 
as protein-coding regions [1], a large part of the genome gives 
rise to noncoding RNAs (ncRNAs), which have little or no 
protein-coding capability. The ncRNAs can be categorized 
into several groups, long non-coding RNAs (lncRNAs), such 
as microRNAs (miRNAs), small interfering RNAS 
(siRNAs), small nuclear (snRNAs), small nucleolar RNAs 
(snoRNAs), and piwi-interacting RNAs (piRNAs), etc. 
NcRNA may play a crucial role in cellular proliferation, 
physiology and pathologies although initially considered to 
be transcriptional noise or artifacts [2, 3].  
NcRNAs can also be grouped into two major groups 
according to their size. Small ncRNAs are transcribed RNA 
molecules shorter than 200 nucleotides, which include 
miRNA, siRNA, piRNA, etc, and lncRNA, which are usually 
longer than 200 nucleotides and are mostly transcribed by 
RNA pol II from different regions across the genome. 
LncRNAs are classified by their position relative to coding 
genes, therefore, they are usually defined as sense, antisense, 
or bidirectional when their transcription is initiated in close 
proximity and opposite orientation to a neighboring coding 
transcript, intronic if it is derived wholly from within an 
intron of a second transcript, and intergenic or intervening 
when it lies within the genomic interval between two genes 
[4]. They play diverse structural and regulatory roles in cells 
such as chromatin modification, transcription, and 
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posttranscriptional processing. Except for diverse biological 
processes, different studies have already shown that aberrant 
lncRNA expression may result in the progression of human 
diseases, including cancers [3].  
In this review, we describe the roles of long-non coding 
RNA SPRY4-IT1 as one of the most important regulatory 
RNAs in human cells, and discuss the implication of 
SPRY4-IT1 for diagnosis, assessment and treatment of 
different diseases. 
Long non-coding RNA SPRY4-IT1 
SPRY4, a member of Sprouty family of genes, is an 
inhibitor of the receptor-transduced mitogen-activated 
protein kinase (MAPK) signaling pathway through inhibit 
the Rat Sarcoma/Extracellular regulated protein kinases 
(Ras/Erk) encoding. It could activate the RAS gene, an 
oncogene, and impairs the formation of active GTP-RAS [5]. 
Studies have identified SPRY4 as a tumor suppressor in 
acute myeloid leukemia [6], non-small cell lung cancer [7], etc. 
Khaitan et al originally reported that SPRY4-IT1 (708 bp) 
was derived from an intronic region within the SPRY4 gene 
and was predicted to contain several long hairpins in its 
secondary structure, and may play an important role in 
melanoma pathogenesis in humans [8]. SPRY4-IT1 transcript 
size is approximately 1.8 kb, and it is proposed to carry both 
intronic and exonic sequences and can be considered as a 
noncoding splice variant of the SPRY4 gene [9]. Additionally, 
studies show that the transcription and function of 
SPRY4-IT1 is independent from its host gene SPRY4 
although they may be regulated by the same transcriptional 
machinery [9]. Studies show that SPRY4 expression levels 
were not significantly changed after SPRY4-IT1 knockdown, 
suggesting that SPRY4-IT1 directly rather than SPRY4 
indirectly induced the phenotypic changes following the 
knockdown of SPRY4-IT1 [10]. 
SPRY4-IT1 as a novel biomarker in various diseases 
Recently, an increasing number of studies have shown that 
aberrant expression of lncRNA SPRY4-IT1 occurs in various 
diseases more than tumors, and SPRY4-IT1 appears different 
phenotype and function according to different diseases, 
indicating SPRY4-IT1 may be a potential diagnostic and 
prognostic biomarker.  
SPRY4-IT1 and different Solid Tumors 
In 2011, researchers initially reported that expression of 
the lncRNA SPRY4-IT1 in melanoma cells is higher than in 
normal human melanocytes [8]. Knockdown of SPRY4-IT1 
blocked melanoma cell invasion and proliferation, and 
increases apoptosis, indicating that the abnormal 
upregulation of SPRY4-IT1 expression may have an 
important role in the molecular etiology of human melanoma 
[8]. Moreover, In esophageal squamous cell carcinoma 
(ESCC) patients, studies showed that SPRY4-IT1 levels were 
significantly higher not only in ESCC tissues and cells [10], 
but also in patients plasm samples [11], and the ESCC patients 
with higher SPRY4-IT1 expression had an advanced clinical 
stage and poor prognosis than those with lower SPRY4-IT1 
expression. Moreover,studies also found that SPRY4-IT1 is 
up-regulated and associated with aggressive progression and 
poor prognosis in renal cancer [12], gastric cancer [13], breast 
cancer [14] and bladder cancer [15], indicating that SPRY4-IT1 
may become a novel potential prognostic biomarker for these 
malignant solid tumors. 
In contrast to the over-expression of SPRY4-IT1 in the 
cancers previously mentioned, SPRY4-IT1 was 
downregulated in Non-small-cell lung cancer (NSCLC), and 
correlated with a poor prognosis of NSCLC. The high level 
of SPRY4-IT1 expression led to the significant inhibition of 
cell proliferation, migration, invasion, and the promotion of 
apoptosis, while knockdown of SPRY4-IT1 expression 
promoted cell migration and invasion [16]. These studies 
suggest SPRY4-IT1 may play complex roles and involves in 
various molecular mechanism in different cancers. 
SPRY4-IT1 and preeclampsia 
Zou et al found a higher expression level of SPRY4-IT1 in 
preeclampsic placental tissues as compared with the normal 
pregnancies [17]. In Trophoblast Cells (HTR-8/SVneo cells), 
the inhibition of SPRY4-IT1 led to the increase of migration 
rate and proliferation and the decrease of their apoptosis rate, 
while reverse results were observed in vitro when 
SPRY4-IT1 was overexpressed [17]. These phenomenon is 
contrary to most of malignant tumors above, indicating 
LncRNAs SPRY4-IT1 may show various phenotypes in 
different tissues and different stages of disease process. 
Moreover, this study found lncRNA SPRY4-IT1 might also 
partly taken part in the process of spiral artery remodeling in 
preeclampsia. 
SPRY4-IT1 functions through various molecular 
mechanism  
The molecular mechanism of lncRNA SPRY4-IT1 
functions in different diseases is complicated, and to further 
explore the molecular mechanism could contribute to fully 
understand diseases including cancer conversely. 
Up-regulate the expression of cyclin D1, MMP2, and 
MMP9 
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Cyclin D1 is a member of highly conserved cyclin family 
[18]. Overexpression of cyclin D1 could alter cell cycle 
progression. MMP2 andMMP9 belong to the matrix 
metalloproteinases (MMP) gene family, and they are 
involved in cell motility, and matrix invasion [19]. Studies 
showed that the inhibition of SPRY4-IT1 significantly lead 
to the downregulation of cyclin D1, MMP2 and MMP9 
expression level, which means SPRY4-IT1 was positively 
correlated with cyclin D1, MMP2, and MMP9 expression [13, 
14]. These findings indicate that SPRY4-IT1 may affect tumor 
cells proliferation, migration, and invasion partly via 
regulating cyclin D1, MMP2, and MMP9 expression. 
Involvement in epithelial–mesenchymal transition (EMT) 
The epithelial–mesenchymal transition (EMT) is the 
process of cells conversing from a differentiated epithelial 
state into a dedifferentiated migratory mesenchymal 
phenotype, which plays a pivotal role in remodeling 
embryogenesis and is implicated in the promotion of tumor 
cell invasion and metastasis [20]. Recently, studies found 
decreased SPRY4-IT1 expression inhibited E-cadherin 
expression and promoted vimentin expression, while 
increased SPRY4-IT1 expression levels could induce 
E-cadherin expression and decrease that of vimentin [16]. This 
study indicate that SPRY4-IT1 affects NSCLC cell 
proliferation and metastasis partly via the epithelial–
mesenchymal transition (EMT), which advances our 
understanding of the role of SPRY4-IT1 as regulators of 
different tumors such as NSCLC pathogenesis. 
Coordination with lipin 2 
Mazar et al purified SPRY4-IT1 from melanoma cells and 
used mass spectrometry to identify the protein lipin 2 as a 
major binding partner, which is an enzyme that could convert 
phosphatidate to diacylglycerol (DAG) [21]. Inhibition of 
SPRY4-IT1 rises theaccumulation of lipin2 protein and 
upregulate the expression of diacylglycerol O-acyltransferase 
2 (DGAT2), an enzyme that could catalyze DAG to 
triacylglycerol (TAG), and induces significant changes in a 
number of lipid species, including increased acyl carnitine, 
fatty acyl chains, and triacylglycerol (TAG) [21]. These results 
suggest SPRY4-IT1 may regulate cell proliferation by lipin 
2-mediated alterations in lipid metabolism in melanoma. 
Regulate ZNF703 gene 
ZNF703, a member of zinc finger transcription factors, is 
located on chromosomes 8 (8p11.23), contributes to aspects 
of growth and patterning across evolutionarily diverse 
species [22]. ZNF703 has been identified as a novel oncogene 
in human breast cancer [23], colorectal cancer [24], gastric 
cancer [22], etc. ZNF703 has been demonstrated promotes 
ER(−) breast carcinoma cell proliferation and suppresses 
apoptosis in vivo, and recently studies showed that ZNF703 
could be regulated by SPRY4-IT1 as a downstream target 
gene of SPRY4-IT1 [14]. Nevertheless, it still remains unclear 
and requires further investigation about the precise molecular 
mechanism regulating how SPRY4-IT1 controls ZNF703. 
Regulation of SPRY4-IT1 
Zeste homolog 2 (EZH2) is a methyltransferase and the 
core catalytic subunit of polycomb repressive complex 2. It 
plays an essential role in the epigenetic maintenance of the 
histone H3 trimethylation (H3K27me3) repressive chromatin 
mark [25]. Sun et al found that the expression of 
SPRY4-IT1significantly upregulated after knockdown of 
EZH2 expression, while chromatin immunoprecipitation 
assays showed that inhibition of EZH2 expression prevented 
its binding to the SPRY4-IT1 promoter region and reduced 
H3K27me3 modification, which upregulated SPRY4-IT1 
expression, suggesting that the epigenetic factor EZH2 could 
regulate the transcript levels of SPRY4-IT1 via H3K27me3 
modification [16]. However, the understanding about cellular 
molecular mechanism that may regulate SPRY4-IT1 
expression at multiple levels is extremely limited so far. 
Prospect 
Accumulating evidence demonstrates the crucial roles of 
SPRY4-IT1 in the initiation and progression of various 
diseases. Exploring the biological roles of SPRY4-IT1 in 
different types of diseases including cancer may help us to 
determine the efficiency of SPRY4-IT1 as a diagnostic or 
predictive biomarker. However, further understading of the 
complex molecular mechanism of long non-coding RNA 
SPRY4-IT1 in the pathogenesis and progressing of different 
diseases is still needed with conduction of clinical trials in 
the future to find this RNA as a suitable biomarker or 
therapeutic target in cancer or other diseases. Besides, 
SPRY4-IT1 can also be further considered as a therapeutic 
target to improve the sensitivity of therapy for different 
diseases. Moreover, the efficacy of these therapeutic 
approaches can be further expanded via identification of 
exact molecular pathways underlying the regulation of 
SPRY4-IT1 expression. 
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